OCTAPHARMA
6.2.2020 10:03:07 CET | Business Wire | Press release
Octapharma had a prominent role as a Sponsor of the 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) Congress this week, which takes place in The Hague, The Netherlands, from February 5–7, 2020. Octapharma’s activities at the Congress included a scientific symposium that focused on addressing the needs of patients with haemophilia A.
The symposium “Unravelling the challenges of haemophilia A: Efficacy, immunogenicity and inhibitor management with Nuwiq® (simoctocog alfa) ” discussed the latest developments with Nuwiq® , a recombinant FVIII (rFVIII) of human cell line origin, as well as new approaches to improve understanding of the optimal treatment approach for each individual with haemophilia A. The symposium was chaired by Maria Elisa Mancuso (Ospedale Maggiore Policlinico, Milan, Italy).
Leading experts presented key data on the efficacy and immunogenicity of Nuwiq® . John Pasi (The Royal London Hospital, London, UK) described the outcomes of patients who followed a different prophylaxis regimen based on individual pharmacokinetic (PK) assessment in the NuPreviq study. The large majority (90%) of the 40 patients remained free from spontaneous bleeds during personalised prophylaxis with Nuwiq® , and 85% (34/40) of patients were treated twice weekly or less, demonstrating the value of personalised prophylaxis with Nuwiq® for identifying patients who can benefit from less frequent dosing while maintaining effective bleed protection. The Nuwiq® Summary of Product Characteristics was revised in 2019 to include these data. John Pasi also shared updates on tools for population-based PK analysis to guide prophylaxis.
For previously untreated patients (PUPs), the risk of inhibitor development remains a concern. Ri Liesner (Great Ormond Street Hospital, London, UK) presented the final results of NuProtect, the largest prospective study of a single FVIII product (Nuwiq® ) in true PUPs. The cumulative incidence of inhibitors and of high-titre inhibitors in 105 PUPs receiving Nuwiq® was 27.9% and 17.6%, respectively. Dr Liesner also highlighted that no PUPs with non-null F8 mutations developed inhibitors in the NuProtect study. These data suggest that Nuwiq® exhibits an immunogenicity profile more similar to that of plasma-derived FVIII containing von Willebrand factor (VWF) than that of rFVIII products derived from hamster cell lines analysed in the SIPPET study 1,2 .
The symposium continued with an informative overview by Carmen Escuriola (Haemophilia Centre Rhein Main, Mörfelden-Walldorf, Germany) of ongoing strategies to understand the impact of different treatment approaches for patients with haemophilia A and inhibitors. Increased understanding of factors impacting induction of immune tolerance and the impact of treatment strategies on long-term outcomes, including joint health, will help to inform treatment decisions for inhibitor patients.
To complete the symposium, Sander Botter, a scientist from the Balgrist Campus AG, Zürich, Switzerland, discussed the roles of FVIII within and beyond haemostasis and the wider importance of FVIII in the context of treating haemophilia A. Dr Botter highlighted the evidence that FVIII may be critical for joint and bone health, and presented new studies that hope to characterise the impact of treatment choice on bone and joint health in people with haemophilia A.
“We are proud to be able to continue to share excellent data with Nuwiq® that demonstrate its value for meeting the needs of each individual with haemophilia A, from the first treatment to long-term protection”, said Dr Larisa Belyanskaya, Head of IBU Haematology at Octapharma.
Olaf Walter, Board Member at Octapharma, added that “This symposium truly demonstrates our commitment at Octapharma to improving the lives of people with bleeding disorders. We are proud to be able to continue to share the benefits of Nuwiq® , which we believe reflect the success of our approach to develop a recombinant FVIII of human cell line origin” .
About Haemophilia A
Haemophilia A is an X-linked hereditary bleeding disorder caused by a deficiency of factor VIII (FVIII) which, if left untreated, may lead to haemorrhages in muscles and joints and consequently to arthropathy and severe morbidity. The disorder affects around one in every 10,000 males worldwide. Prophylaxis with replacement FVIII therapy reduces the number of bleeding episodes and the risk of permanent joint damage.
About Nuwiq®
Nuwiq® (simoctocog alfa) is a 4th generation recombinant factor VIII (rFVIII) protein, produced in a human cell line without chemical modification or fusion with any other protein3 . It is cultured without additives of human or animal origin, is devoid of antigenic non-human protein epitopes and has a high affinity for von Willebrand factor3 . Nuwiq® treatment has been assessed in seven completed clinical trials which included 201 previously treated patients (PTPs; 190 individuals) with severe haemophilia A, including 59 children3 . Treatment of previously untreated patients (PUPs) with Nuwiq® was assessed in the NuProtect study. Nuwiq® is available in 250 IU, 500 IU, 1000 IU, 2000 IU, 2500 IU, 3000 IU and 4000 IU presentations4 . Nuwiq® is approved in 61 countries for use in the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital FVIII deficiency) across all age groups5 .
About Octapharma
The vision of Octapharma is: “Our passion drives us to provide new health solutions advancing human life”. Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. As a family-owned company, Octapharma believes in investing to make a difference in people’s lives and has been doing so since 1983; because it’s in our blood. Our company values are Ownership, Integrity, Leadership, Sustainability and Entrepreneurship.
Octapharma employs 8,314 people worldwide to support the treatment of patients in 115 countries with products across three therapeutic areas:
- Haematology (coagulation disorders)
- Immunotherapy (immune disorders)
- Critical care (bleeding management and functional volume replacement)
Octapharma has seven R&D sites and six state-of-the-art manufacturing facilities in Austria, France, Germany, Mexico and Sweden.
1 Peyvandi F et al. N Engl J Med 2016; 374:2054-64.
2 Liesner RJ et al Blood . 2018; 13 March (e-letter).
3 Lissitchkov T et al. Ther Adv Hematol 2019; doi: 10.1177/2040620719858471.
4 Nuwiq Summary of Product Characteristics.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200206005356/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OCP Announces Date of Third Quarter and Nine-Month 2026 Earnings19.11.2026 17:30:00 CET | Press release
OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its third quarter and nine-month 2026 results on Monday, November 30, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 7:00 a.m. EDT, 12:00 p.m. Morocco and London time (GMT). OCP senior management will host a conference call to discuss third quarter and nine-month 2026 results at 8:00 a.m. EDT, 1:00 p.m. Morocco and London time (GMT) on Monday, November 30, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s production history. OCP has exclusive ac
ISACA Launches Updated COBIT 7 With Enhanced Assessment Model and Modern Digital Platform19.11.2026 16:24:00 CET | Press release
Refreshed framework reflects today’s technology landscape with streamlined design guidance, refreshed objectives and three levels of organizational assessment When AI can spark fears about humanity’s future and aging technology can bring air travel to a standstill, the cost of weak governance is impossible to ignore. To help enterprises strengthen the governance of their information and technology, ISACA has launched COBIT 7, an updated version of its globally recognized framework for information and technology (I&T) governance. Built for a rapidly changing digital world, the new COBIT 7 framework combines trusted guidance, an intuitive digital platform, customizable resources, and practical tools to help practitioners turn technology into measurable value, align decisions with strategy and confidently navigate emerging risks, including AI. COBIT 7 reinforces the framework’s longstanding role in helping businesses align their I&T operations with broader strategic goals, manage technolo
North Star Carbon Removal Project Selected by Government of Canada for Landmark Carbon Removal Procurement Program19.11.2026 16:04:00 CET | Press release
Microsoft-backed Saskatchewan project developed by MLTC and Svante among only three BECCS projects selected North Star, a planned large-scale carbon dioxide removal (CDR) project being developed by Meadow Lake Tribal Council (MLTC) and Svante Technologies Inc. (Svante), has been selected by the Government of Canada as a qualified supplier under the federal Request for Standing Offer (RFSO) for the Acquisition and Retirement of Credits from Carbon Dioxide Removal Projects. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118228180/en/ The proposed North Star bioenergy with carbon capture and storage project is being developed by the Meadow Lake Tribal Council (MLTC) and Svante. The project will generate durable carbon dioxide removal credits by capturing biogenic CO2 from the MLTC Bioenergy Center in Meadow Lake, SK, Canada, and storing it deep underground in a geological storage site. North Star was one of only three bioene
Xsolla Gives Games a New Home for Their Players on Desktop and the Web, With Rewards to Help Bring Players Back19.11.2026 15:32:00 CET | Press release
Developers Can Now Reach Players on Desktop and the Web With Xsolla Player and Xsolla Pages Xsolla (USA), Inc., a global commerce company, is giving game developers two new capabilities designed to reach players and encourage repeat engagement. Xsolla Player and Xsolla Pages are now available, letting developers integrate quests, rewards, and partner-funded offers into the player flow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119175727/en/ Graphic: Xsolla Xsolla Player is a desktop app that players install once and access with their Xsolla ID, bringing their game library and inventory together without separate sign-ups for each game. Xsolla Pages creates search-optimized storefronts on the web for every title in a developer’s catalog, with direct checkout. PC studios work hard to win a player's first click, then work just as hard for every session after. Bringing players back is a challenge and has traditionally req
From London 1851 to Riyadh 2030: The United Kingdom Continues Its World Expo Legacy with the Signing of Its Participation Contract for Expo 2030 Riyadh19.11.2026 15:10:00 CET | Press release
The United Kingdom has signed its Participation Contract for Expo 2030 Riyadh, confirming its place at one of the world’s largest global gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119617914/en/ The Participation Contract was signed by H.E Adel Al-Jubeir, Minister of State for Foreign Affairs, Climate Envoy, and Commissioner General of Expo 2030 Riyadh; and Lord Sarwar, UK Minister for Trade; and Talal Al-Marri, CEO of Expo 2030 Riyadh. The Agreement constitutes a significant milestone in the United Kingdom’s journey towards Expo 2030 Riyadh, establishing the framework for the execution of its pavilion, programming and visitor experience. This latest agreement adds to a growing number of Participation Contract signings, reflecting increasing momentum behind Expo 2030 Riyadh and the value countries are placing on being part of it. The Participation Contract was signed by H.E Adel Al-Jubeir, Minister of State
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
